Andrew McGovern
Academic Clinical Fellow (Clin Hon)
A.McGovern@exeter.ac.uk
Publications
Journal articles
Hopkins R, Young K, Thomas N, Godwin J, Raja D, Mateen B, Challen R, Vollmer S, Shields B, McGovern A, et al (In Press). Risk factor associations for severe Covid-19, influenza, and pneumonia in people with diabetes to inform future pandemic preparations: UK population-based cohort study. BMJ Open
Dennis J, Henley W, McGovern A, Farmer A, Sattar N, Holman R, Pearson E, Hattersley A, Shields B, Jones AG, et al (In Press). Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017 Running title: Prescribing and patient outcomes in type 2 diabetes. Diabetes, Obesity and Metabolism
McGovern A, Shields B, Hattersley A, Pearson E, Jones AG (In Press). What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? a MASTERMIND study. BMC Medicine
Semnani-Azad Z, Gaillard R, Hughes AE, Boyle KE, Tobias DK, ADA/EASD PMDI, Perng W (2024). Precision stratification of prognostic risk factors associated with outcomes in gestational diabetes mellitus: a systematic review. Commun Med (Lond), 4(1). Abstract. Author URL.
Harid A, Rowe M, Patel N, Jeffery J, Flannagan D, McGovern A (2023). A pragmatic approach to monitoring for adrenal axis recovery after a failed Short Synacthen Test (SST). Endocrine Abstracts
Young KG, McGovern AP, Barroso I, Hattersley AT, Jones AG, Shields BM, Thomas NJ, Dennis JM (2023). HbA1c screening for the diagnosis of diabetes. Reply to Brož J, Brabec M, Krollová P et al [letter]. Diabetologia, 66(8), 1578-1579. Author URL.
Cardoso P, Young KG, Nair ATN, Hopkins R, McGovern AP, Haider E, Karunaratne P, Donnelly L, Mateen BA, Sattar N, et al (2023). Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Abstract.
Young KG, McInnes EH, Massey RJ, Kahkohska AR, Pilla SJ, Raghaven S, Stanislawski MA, Tobias DK, McGovern AP, Dawed AY, et al (2023). Precision medicine in type 2 diabetes: a systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors. Abstract.
Young KG, Hopkins R, Shields BM, Thomas NJ, McGovern AP, Dennis JM (2023). Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy. Abstract.
Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, Clark AL, Colclough K, Corcoy R, Cromer SJ, et al (2023). Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nature Medicine, 29(10), 2438-2457.
Mayne IK, Tyzack-Clark HM, McGovern AP (2023). Studies are needed to support optimal insulin dose titration in gestational diabetes mellitus: a systematic review. Diabetes & Metabolic Syndrome Clinical Research & Reviews, 17(4).
de Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C, Flohr C (2022). Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study. Journal of Allergy and Clinical Immunology, 150(3), 709-713.
Whyte, Martin B. Joy, Mark, Hinton, William, McGovern, Andrew, Hoang, Uy, van Vlymen, Jeremy, Ferreira, Filipa, Mount, Julie, Munro, Neil, de Lusignan, Simon, et al (2022). Author response for "Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: a primary care cohort study".
William Hinton, Abdus Samad Ansari, Martin B. Whyte, Andrew P. McGovern, Michael D. Feher, Neil Munro, Simon de Lusignan (2022). Author response for "Sodium–glucose co‐transporter‐2 (SGLT2) inhibitors in type 2 diabetes: are clinical trial benefits for heart failure reflected in real‐world clinical practice? a systematic review and meta‐analysis of observational studies".
William Hinton, Abdus Samad Ansari, Martin B. Whyte, Andrew P. McGovern, Michael D. Feher, Neil Munro, Simon de Lusignan (2022). Author response for "Sodium–glucose co‐transporter‐2 (SGLT2) inhibitors in type 2 diabetes: are clinical trial benefits for heart failure reflected in real‐world clinical practice? a systematic review and meta‐analysis of observational studies".
de Lusignan S, McGovern A, Hinton W, Whyte M, Munro N, Williams ED, Marcu A, Williams J, Ferreira F, Mount J, et al (2022). Barriers and Facilitators to the Initiation of Injectable Therapies for Type 2 Diabetes Mellitus: a Mixed Methods Study. Diabetes Therapy, 13(10), 1789-1809.
Whyte MB, Joy M, Hinton W, McGovern A, Hoang U, van Vlymen J, Ferreira F, Mount J, Munro N, de Lusignan S, et al (2022). Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: a primary care cohort study. Diabetes, Obesity and Metabolism, 24(7), 1310-1318. Abstract.
Thomas NJ, McGovern A, Young KG, Sharp SA, Weedon MN, Hattersley AT, Dennis J, Jones AG (2022). Identifying type 1 and 2 diabetes in population level data: assessing the accuracy of published approaches. Abstract.
McGovern AP, Hirwa KD, Wong AK, Holland CJE, Mayne I, Hashimi A, Thompson R, Creese V, Havill S, Sanders T, et al (2022). Patient-led rapid titration of basal insulin in gestational diabetes is associated with improved glycaemic control and lower birthweight. Diabet Med, 39(10). Abstract. Author URL.
Mayne I, Thomas N, McGovern A (2022). Rapid, patient-led titration of basal insulin can be used to achieve tight glycaemic control in gestational diabetes mellitus with insulin resistance. BMJ Case Rep, 15(3). Abstract. Author URL.
Hinton W, Ansari AS, Whyte MB, McGovern AP, Feher MD, Munro N, de Lusignan S (2022). Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? a systematic review and meta‐analysis of observational studies. Diabetes Obesity and Metabolism, 25(2), 501-515.
Young KG, McGovern AP, Barroso I, Hattersley AT, Jones AG, Shields BM, Thomas NJ, Dennis JM (2022). The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis. Diabetologia, 66(2), 300-309. Abstract.
MAYNE IK, THOMAS N, HATTERSLEY AT, MCGOVERN AP (2021). 954-P: in Gestational Diabetes, Patient-Led Insulin Titration is Rapidly Effective without Detrimental Hypoglycaemia. Diabetes, 70(Supplement_1).
Wilde H, Dennis JM, McGovern AP, Vollmer SJ, Mateen BA (2021). A national retrospective study of the association between serious operational problems and COVID-19 specific intensive care mortality risk. PLOS ONE, 16(7), e0255377-e0255377. Abstract.
Dennis JM, Young KG, McGovern AP, Mateen BA, Vollmer SJ, Simpson MD, Henley WE, Holman RR, Sattar N, Pearson ER, et al (2021). Derivation and validation of a type 2 diabetes treatment selection algorithm for SGLT2-inhibitor and DPP4-inhibitor therapies based on glucose-lowering efficacy: cohort study using trial and routine clinical data. Abstract.
Shah S, Feher M, McGovern A, Sherlock J, Whyte MB, Munro N, Hinton W, Gatenby P, de Lusignan S (2021). Diabetic retinopathy in newly diagnosed Type 2 diabetes mellitus: Prevalence and predictors of progression; a national primary network study. Diabetes Res Clin Pract, 175 Abstract. Author URL.
Mateen BA, Wilde H, Dennis JM, Duncan A, Thomas N, McGovern A, Denaxas S, Keeling M, Vollmer S (2021). Hospital bed capacity and usage across secondary healthcare providers in England during the first wave of the COVID-19 pandemic: a descriptive analysis. BMJ Open, 11(1), e042945-e042945. Abstract.
Dennis JM, McGovern AP, Vollmer SJ, Mateen BA (2021). Improving Survival of Critical Care Patients with Coronavirus Disease 2019 in England: a National Cohort Study, March to June 2020. Crit Care Med, 49(2), 209-214. Abstract. Author URL.
de Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C, Flohr C (2021). Patterns and trends in eczema management in UK primary care (2009–2018): a population-based cohort study. Clinical and Experimental Allergy, 51(3), 483-494. Abstract.
Farmer RE, Beard I, Raza SI, Gollop ND, Patel N, Tebboth A, McGovern AP, Kanumilli N, Ternouth A (2021). Prescribing in Type 2 Diabetes Patients with and Without Cardiovascular Disease History: a Descriptive Analysis in the UK CPRD. Clinical Therapeutics, 43(2), 320-335. Abstract.
Ogundipe O, Mazidi M, Chin KL, Gor D, McGovern A, Sahle BW, Jermendy G, Korhonen MJ, Appiah B, Ademi Z, et al (2021). Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes. Acta Diabetol, 58(1), 39-46. Abstract. Author URL.
Simpson V, McGovern A (2021). Recurrent hypoglycemia and a slowly rising hemidiaphragm: a case report. Clinical Case Reports, 9(7). Abstract.
McGovern AP, Thomas NJ, Vollmer SJ, Hattersley AT, Mateen BA, Dennis JM (2021). The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation. Diabetologia, 64(5), 1184-1186. Author URL.
de Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C, Flohr C (2021). The epidemiology of eczema in children and adults in England: a population-based study using primary care data. Clinical and Experimental Allergy, 51(3), 471-482. Abstract.
Dennis JM, McGovern AP, Thomas NJ, Wilde H, Vollmer SJ, Mateen BA (2021). Trends in 28-Day Mortality of Critical Care Patients with Coronavirus Disease 2019 in the United Kingdom: a National Cohort Study, March 2020 to January 2021. Crit Care Med, 49(11), 1895-1900. Abstract. Author URL.
Mateen BA, Wilde H, Dennis JM, Duncan A, Thomas NJ, McGovern AP, Denaxas S, Keeling MJ, Vollmer SJ (2020). A geotemporal survey of hospital bed saturation across England during the first wave of the COVID-19 Pandemic. Abstract.
De Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C, Flohr C (2020). Epidemiology and management of atopic dermatitis in England: an observational cohort study protocol. BMJ Open, 10(9). Abstract.
Dennis JM, McGovern AP, Vollmer SJ, Mateen BA (2020). Improving COVID-19 critical care mortality over time in England: a national cohort study, March to June 2020. Abstract.
Farmer RE, Beard I, Raza S, Gollop ND, Patel N, McGovern A, Kanumilli N, Ternouth A (2020). PDB59 Prescribing Patterns in Type 2 Diabetes By Cardiovascular Disease History: a Descriptive Analysis in the UK Clinical Practice Research Datalink. Value in Health, 23, s515-s516.
McGovern AP, Hogg M, Shields BM, Sattar NA, Holman RR, Pearson ER, Hattersley AT, Jones AG, Dennis JM (2020). Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Research & Care, 8(1), e001238-e001238. Abstract.
Dennis JM, Mateen BA, Sonabend R, Thomas NJ, Patel KA, Hattersley AT, Denaxas S, McGovern AP, Vollmer SJ (2020). Type 2 Diabetes and COVID-19–Related Mortality in the Critical Care Setting: a National Cohort Study in England, March–July 2020. Diabetes Care, 44(1), 50-57. Abstract.
Whyte MB, Hinton W, McGovern A, van Vlymen J, Ferreira F, Calderara S, Mount J, Munro N, de Lusignan S (2019). Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: a retrospective cohort analysis. PLOS Medicine, 16(10), e1002942-e1002942.
Rayner LH, Mcgovern A, Sherlock J, Gatenby P, Correa A, Creagh-Brown B, deLusignan S (2019). The impact of therapy on the risk of asthma in type 2 diabetes. Clinical Respiratory Journal, 13(5), 299-305. Abstract.
Rayner L, McGovern A, Creagh-Brown B, Woodmansey C, De Lusignan S (2019). Type 2 diabetes and asthma: Systematic review of the bidirectional relationship. Current Diabetes Reviews, 15(2), 118-126. Abstract.
McGovern A, Hinton W, Calderara S, Munro N, Whyte M, de Lusignan S (2018). A Class Comparison of Medication Persistence in People with Type 2 Diabetes: a Retrospective Observational Study. Diabetes Therapy, 9(1), 229-242. Abstract.
McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S (2018). Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab, 20(4), 1040-1043. Abstract. Author URL.
Ansari AS, de Lusignan S, Hinton W, Munro N, Taylor S, McGovern A (2018). Glycemic control is an important modifiable risk factor for uveitis in patients with diabetes: a retrospective cohort study establishing clinical risk and ophthalmic disease burden. Journal of Diabetes and its Complications, 32(6), 602-608. Abstract.
Hinton W, McGovern A, Coyle R, Han TS, Sharma P, Correa A, Ferreira F, De Lusignan S (2018). Incidence and prevalence of cardiovascular disease in English primary care: a cross-sectional and follow-up study of the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC). BMJ Open, 8(8). Abstract.
Shankar K, Simon DL, McGovern A, Ana C, Mariya H, Piers G, Simon J, David G, John C (2018). Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. BMJ, 360
Rayner LH, McGovern AP, Sherlock J, Gatenby P, Correa A, Creagh-Brown B, de Lusignan S (2018). Type 2 diabetes: a protective factor for COPD?. Primary Care Diabetes, 12(5), 438-444. Abstract.
Ansari AS, De Lusignan S, Arrowsmith B, Hinton W, Munro N, McGovern A (2017). Association between diabetes, level of glycemic control, and eye infection: a cohort study. Diabetes Care, 40(3), e30-e31.
Hine JL, de Lusignan S, Burleigh D, Pathirannehelage S, McGovern A, Gatenby P, Jones S, Jiang D, Williams J, Elliot AJ, et al (2017). Association between glycaemic control and common infections in people with Type 2 diabetes: a cohort study. Diabetic Medicine, 34(4), 551-557. Abstract.
Tippu Z, Correa A, Liyanage H, Burleigh D, McGovern A, Van Vlymen J, Jones S, De Lusignan S (2017). Ethnicity Recording in Primary Care Computerised Medical Record Systems: an Ontological Approach. BMJ Health & Care Informatics Online, 23(4).
McGovern AP, Fieldhouse H, Tippu Z, Jones S, Munro N, de Lusignan S (2017). Glucose test provenance recording in UK primary care: was that fasted or random?. Diabet Med, 34(1), 93-98. Abstract. Author URL.
McGovern A (2017). Glycaemic control in the elderly: What should we be aiming for?. Journal of Diabetes Nursing, 21(4), 133-137. Abstract.
de Lusignan S, Hayward N, McGovern A, Arrowsmith B, Jones S (2017). INTERNATIONAL PERSPECTIVES IN PRIMARY CARE OF OLDER ADULTSPHOSPHATE AND CALCIUM ASSOCIATION WITH CARDIAC EVENTS IN OLDER PEOPLE: RETROSPECTIVE COHORT ANALYSIS. Innovation in Aging, 1(suppl_1), 699-699.
Woodmansey C, McGovern AP, McCullough KA, Whyte MB, Munro NM, Correa AC, Gatenby PAC, Jones SA, de Lusignan S (2017). Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): a Retrospective Cohort Study. Diabetes Care, 40(11), 1486-1493. Abstract.
Hinton W, Liyanage H, McGovern A, Liaw S-T, Kuziemsky C, Munro N, de Lusignan S (2017). Measuring Quality of Healthcare Outcomes in Type 2 Diabetes from Routine Data: a Seven-nation Survey Conducted by the IMIA Primary Health Care Working Group. Yearbook of Medical Informatics, 26(01), 201-208.
Hinton W, Liyanage H, McGovern A, Liaw ST, Kuziemsky C, Munro N, de Lusignan S (2017). Measuring Quality of Healthcare Outcomes in Type 2 Diabetes from Routine Data: a Seven-nation Survey Conducted by the IMIA Primary Health Care Working Group. Yearbook of medical informatics, 26(1), 201-208. Abstract.
McGovern A, Feher M, Munro N, de Lusignan S (2017). Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol). Diabetes Therapy, 8(2), 355-363. Abstract.
McGovern A, Feher M, Munro N, de Lusignan S (2017). Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use. Diabetes Therapy, 8(2), 365-376. Abstract.
Ansari AS, de Lusignan S, Hinton W, Munro N, McGovern A (2017). The association between diabetes, level of glycaemic control and eye infection: Cohort database study. Primary Care Diabetes, 11(5), 421-429. Abstract.
Hayward N, McGovern A, De Lusignan S, Cole N, Hinton W, Jones S (2017). U-shaped relationship between serum phosphate and cardiovascular risk: a retrospective cohort study. PLoS ONE, 12(11). Abstract.
Gabriel J, McGovern A, Robinson S, Wright D, Chevassut T (2016). A systematic study comparing aspirate versus trephine for quantifying plasma cell infiltration in newly-diagnosed myeloma. Br J Haematol, 174(5), 818-820. Author URL.
McGovern AP, Hine J, de Lusignan S (2016). Infection risk in elderly people with reduced glycaemic control. Lancet Diabetes Endocrinol, 4(4), 303-304. Author URL.
De Lusignan S, McGovern AP, Tahir MA, Hassan S, Jones S, Halter M, Joly L, Drennan VM (2016). Physician associate and general practitioner consultations: a comparative observational video study. PLoS ONE, 11(8). Abstract.
McGovern A, Hinton W, Correa A, Munro N, Whyte M, de Lusignan S (2016). Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK. BMJ OPEN, 6(11). Author URL.
Correa A, Hinton W, McGovern A, van Vlymen J, Yonova I, Jones S, de Lusignan S (2016). Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile. BMJ Open, 6(4). Abstract. Author URL.
McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S (2016). Systematic review of adherence rates by medication class in type 2 diabetes: a study protocol. BMJ Open, 6(2). Abstract. Author URL.
McGovern AP, Woodman J, Allister J, van Vlymen J, Liyanage H, Jones S, Rafi I, de Lusignan S, Gilbert R (2015). A simple clinical coding strategy to improve recording of child maltreatment concerns: an audit study. J Innov Health Inform, 22(1), 227-234. Abstract. Author URL.
McGovern A, Hinchliffe R, Munro N, de Lusignan S (2015). Basing approval of drugs for type 2 diabetes on real world outcomes. BMJ, 351 Author URL.
Poh N, McGovern AP, de Lusignan S (2015). Improving the measurement of longitudinal change in renal function: automated detection of changes in laboratory creatinine assay. J Innov Health Inform, 22(2), 293-301. Abstract. Author URL.
Chowdhury B, McGovern A, Cui Y, Choudhury SR, Cho I-H, Cooper B, Chevassut T, Lossie AC, Irudayaraj J (2015). The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells. Sci Rep, 5 Abstract. Author URL.
McGovern A, van Vlymen J, Liyanage H, Jones S, de Lusignan S, Woodman J, Gibert R, Allister J, Rafi I (2014). A simple clinical coding strategy to improve recording of child maltreatment concerns: an audit study. Br J Gen Pract, 64(625), 389-390. Author URL.
Bisling KE, Brewin JN, McGovern AP, Horne GA, Rider T, Stewart HJ, Ramsahoye BH, Chevassut TJ (2014). DNMT3A mutations at R882 hotspot are only found in major clones of acute myeloid leukemia. Leuk Lymphoma, 55(3), 711-714. Author URL.
McGovern AP, Dutta N, Munro N, Watters K, Feher M (2014). Dapagliflozin: Clinical practice compared with pre-registration trial data. British Journal of Diabetes and Vascular Disease, 14(4), 138-143. Abstract.
McGovern A, Butler L, Jones S, van Vlymen J, Sadek K, Munro N, Carr H, de Lusignan S (2014). Diabetes screening after gestational diabetes in England: a quantitative retrospective cohort study. Br J Gen Pract, 64(618), e17-e23. Abstract. Author URL.
Rafiq M, McGovern A, Jones S, Harris K, Tomson C, Gallagher H, de Lusignan S (2014). Falls in the elderly were predicted opportunistically using a decision tree and systematically using a database-driven screening tool. J Clin Epidemiol, 67(8), 877-886. Abstract. Author URL.
McGovern AP, Jones S, van Vlymen J, Saggar AK, Sandford R, de Lusignan S (2014). Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study. BMC Nephrol, 15 Abstract. Author URL.
Brownrigg JRW, de Lusignan S, McGovern A, Hughes C, Thompson MM, Ray KK, Hinchliffe RJ (2014). Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart, 100(23), 1837-1843. Abstract. Author URL.
McGovern AP, Munro N, Watters K, Feher M (2014). Profound weight reduction with GLP-1 agonist therapy: a delayed hyper-response. Practical Diabetes, 31(7), 286-286a.
McGovern AP, Rusholme B, Jones S, van Vlymen JN, Liyanage H, Gallagher H, Tomson CRV, Khunti K, Harris K, de Lusignan S, et al (2013). Association of chronic kidney disease (CKD) and failure to monitor renal function with adverse outcomes in people with diabetes: a primary care cohort study. BMC Nephrol, 14 Abstract. Author URL.
Lusignan SD, Gallagher H, Jones S, Chan T, van Vlymen J, Tahir A, Thomas N, Jain N, Dmitrieva O, Rafi I, et al (2013). Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results. Kidney Int, 84(3), 609-620. Abstract. Author URL.
De Lusignana S, Gallagher H, Jones S, Chan T, Van Vlymen J, Tahir A, Thomas N, Jain N, Dmitrieva O, Rafi I, et al (2013). Erratum: Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results (Kidney International (2013) 84 (609-620) DOI:10.1038/ki.2013.96). Kidney International, 84(6).
McGovern AP, de Lusignan S, van Vlymen J, Liyanage H, Tomson CR, Gallagher H, Rafiq M, Jones S (2013). Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study. PLoS One, 8(9). Abstract. Author URL.
McGovern AP, Powell BE, Chevassut TJT (2012). A dynamic multi-compartmental model of DNA methylation with demonstrable predictive value in hematological malignancies. J Theor Biol, 310, 14-20. Abstract. Author URL.
Chapters
Brooke A, McGovern A (2022). Endocrinology and ageing. In (Ed) Oxford Handbook of Endocrinology & Diabetes 4e, Oxford University PressOxford, 703-718. Abstract.
Conferences
Mayne IK, Thomas NJ, Hirwa KD, Wong AK, Holland CJE, Hashimi A, Hattersley AT, McGovern AP (2021). In gestational diabetes, patient-led insulin titration is rapidly effective, safe and results in a significant reduction in birthweight. Author URL.
Shah S, Whyte MB, McGovern A, Van Vlymen JN, Hinton W, Munro N, de Lusignan S (2018). Disparities in prescribing of sodium-glucose co-transporter-2 (SGLT2) inhibitors and DPP-4 inhibitors in people with Type 2 diabetes and chronic kidney disease (CKD). Author URL.
Whyte MB, Shah S, McGovern A, van Vlymen J, Hinton W, Munro N, de Lusignan S (2018). Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular death with empagliflozin? Results from EMPA-REG OUTCOME. Author URL.
Konstantara E, McGovern AP, Hinton W, Coyle R, Feher M, Munro N, de Lusignan S (2018). GLP-1 RA treatment: a benefit-risk analysis from a retrospective cohort study. Author URL.
McGovern A, Dennis J, Shields B, Pearson E, Hattersley A, Jones A (2018). HbA<sub>1c</sub> is highly variable in people with type 2 diabetes on stable therapy in both trial and real-world settings: implications for clinical practice. Author URL.
Mcgovern AP, Rogers L, Weedon M, Shields B, Pearson E, Hattersley AT, Jones A (2018). Is there benefit from continuing glucose lowering therapies which have a poor initial response in Type 2 diabetes?. Author URL.
McGovern A, Hinton W, de Lusignan S (2017). A national audit of SGLT2 use in England. Author URL.
Hinton W, McGovern A, Arrowsmith B, Munro N, Whyte M, de Lusignan S (2017). Disparities in the monitoring and complication screening of people with Type 2 diabetes. Author URL.
Whyte MB, McGovern A, Hinton W, Arrowsmith B, de Lusignan S (2017). Does the presence of NAFLD influence prescribing behaviour in Type 2 diabetes?. Author URL.
Hinton W, McGovern AP, Calderara S, Munro N, Whyte M, de Lusignan S (2017). Ethnic and socioeconomic disparities in type 2 diabetes care: a trend analysis. Author URL.
McGovern A, Hinton W, Arrowsmith B, Munro N, Whyte M, de Lusignan S (2017). Inadequate diabetes control is more prevalent in South Asians than Europeans: potential role of therapeutic inertia. Author URL.
Ansari AS, de Lusignan S, Arrowsmith B, Hinton W, McGovern A (2017). Is diabetes really a risk factor for acute eye infection?. Author URL.
Hinton W, Mcgovern A, Munro N, De Lusignan S, Whyte MB (2017). Patient Characteristics Associated with Poor Glycaemic Control at Diagnosis of Type 2 Diabetes. Author URL.
Coleman M, Hinton W, McGovern A, de Lusignan S, Shawe J (2017). Preconception folic acid uptake in women with diabetes of childbearing age: findings from the Royal College of General Practitioners Research Surveillance Centre. Author URL.
Whyte M, Hoang U, Hinton W, McGovern AP, Munro N, de Lusignan S (2017). Real world evidence for legacy effect of early glycaemic control in type 2 diabetes on risk of macrovascular disease. Author URL.
Woodmansey C, McCullough K, McGovern A, Hinton W, Arrowsmith B, Correa A, Munro N, Gatenby P, de Lusignan S (2017). The distinct epidemiology of 'Type 3c' diabetes should prompt consideration of chronic pancreatic disease as the possible cause of a patient's diabetes. Author URL.
Ansari AS, de Lusignan S, Arrowsmith B, Hinton W, McGovern A (2017). The relationship between diabetes, retinopathy, glycaemic control, acute uveitis, and scleritis. Author URL.
McGovern AP, Hoang U, Hinton W, Munro N, Calderara S, de Lusignan S, Whyte M (2017). What predicts early glycaemic control in people with type 2 diabetes?. Author URL.
McGovern AP, Hinton W, Curtis BH, van Brunt K, Calderara S, de Lusignan S (2016). Differences in persistence by class of oral therapy for the treatment of type 2 diabetes. Author URL.
Mcgovern AP, Hinton W, Munro NM, Whyte MB, De Lusignan S (2016). Do Persistence Rates Vary between Dipeptidylpeptidase-4 Inhibitors?. Author URL.
Mcgovern AP, Hinton W, Tippu Z, Whyte M, De Lusignan S (2016). Ethnic Disparities in Medication Persistence in Type 2 Diabetes: Non-Whites Have Reduced Persistence. Author URL.
Tippu Z, Liyanage H, Correa A, Burleigh D, McGovern A, Jones S, de Lusignan S (2016). Ontologies to improve the identification of ethnicity in people with Type 2 diabetes. Author URL.
Hinton W, McGovern AP, van Vlymen J, Munro N, Whyte M, Jones S, de Lusignan S (2016). Poor glycaemic control is associated with higher serum triglyceride levels in clinical practice. Author URL.
Mcgovern AP, Hinton W, van Vlymen J, Munro N, Whyte M, de Lusignan S (2016). Real-world evidence on prescribing trends in sodium glucose cotransporter 2 inhibitors in UK primary care. Author URL.
McGovern AP, Hinton W, van Vlymen J, Munro N, Whyte M, de Lusignan S (2016). Real-world evidence on the disparities in prescribing of dipeptidylpeptidase-4 inhibitors in UK primary care. Author URL.
Hinton W, McGovern AP, van Vlymen J, Munro N, Whyte M, de Lusignan S (2016). Real-world evidence on the prescribing trends of glucagon-like peptide-1 agonists in UK primary care. Author URL.
Mcgovern AP, Hine J, De Lusignan S (2016). The Incidence of Infection is Higher in Older People with Poor Glycemic Control. Author URL.
Hinton W, McGovern AP, Whyte M, Curtis BH, McCullough K, van Brunt K, Calderara S, de Lusignan S (2016). What are the HbA<sub>1c</sub> thresholds for initiating insulin therapy in people with type 2 diabetes in UK primary care?. Author URL.
Mcgovern AP, Dutta N, Watters K, Munro N, Feher M (2015). Additive weight loss effect with a combination of an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) agonist in Type 2 diabetes. Author URL.
McGovern AP, Munro N, Chan T, Jones S, De Lusignan S (2014). People with common mental health problems and diabetes receive better surveillance of diabetes related conditions and equal surveillance of their diabetes in primary care. Author URL.
Brownrigg JRW, de Lusignan S, McGovern A, Thompson MM, Ray KK, Hinchliffe RJ (2014). Peripheral neuropathy and the risk of cardiovascular events in diabetes mellitus. Author URL.
Mcgovern AP, Rusholme B, de Lusignan S, van Vlymen J, Jones S (2013). People with diabetes and unmonitored renal function are at increased risk of an adverse outcome: a cohort study. Author URL.
Brownrigg J, McGovern A, DeLusignan S, Ray K, Hinchliffe R (2013). Peripheral Neuropathy is an Independent Predictor of Cardiovascular Events Among Individuals with Diabetes Mellitus. Author URL.
Mcgovern AP, Rafiq M, Munro NM, Butler LI, Russell-Jones D, Jones S, Hinchliffe R, De Lusignan S (2013). Peripheral Sensory Neuropathy is an Important Indicator of Mortality in People with Diabetes. Author URL.
Butler L, McGovern AP, de Lusignan S, Jones S (2013). Postnatal monitoring for diabetes following gestational diabetes in the UK. Author URL.
Mcgovern AP, Rusholme B, de Lusignan S, van Vlymen J, Jones S (2013). The interrelationship between hypertension, chronic kidney disease and proteinuria in people with diabetes: a cohort study. Author URL.
